Market Research Industry Reports

Canavan Disease - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Canavan Disease - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H1 2018, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.

Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the buildup of N-acetylaspartic acid (NAA) in the brain. The buildup of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, and an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Canavan Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Canavan Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Canavan Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Canavan Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Canavan Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Canavan Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Canavan Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Canavan Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Canavan Disease - Overview
Canavan Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Canavan Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Molecule Type
Canavan Disease - Companies Involved in Therapeutics Development
Pfizer Inc
Canavan Disease - Drug Profiles
Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Canavan Disease - Dormant Projects
Canavan Disease - Discontinued Products
Canavan Disease - Product Development Milestones
Featured News & Press Releases
Nov 09, 2017: New gene therapy developed with UNSW researchers targets brain disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Canavan Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Canavan Disease - Pipeline by Pfizer Inc, H1 2018
Canavan Disease - Dormant Projects, H1 2018
Canavan Disease - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Canavan Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Canavan Disease - Pipeline Review, H1 2018

Canavan Disease - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H1 2018, provides an overview of the Canavan Disease

USD 2000View Report

Canavan Disease - Pipeline Review, H2 2017

Canavan Disease - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H2 2017, provides an overview of the Canavan Disease

USD 2000View Report

Alzheimers Disease - Pipeline Review, H2 2018

Alzheimers Disease - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Alzheimers Disease - Pipeline Review, H2 2018, provides an overview of the Alzheimers Disease (Central Nervous

USD 2500View Report

Degenerative Disc Disease - Pipeline Review, H2 2018

Degenerative Disc Disease - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Pipeline Review, H2 2018, provides an overview of the Degenerative Disc

USD 2000View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jun 2018
No. of Pages :28
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube